Cedilla Therapeutics, Inc. — Form D/A
Cedilla Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2021-09-09. The offering totals $60.0M, of which $57.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-09-09
- Form: D/A
- Accession: 0001824618-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $60.0M
- Amount sold: $57.6M
- Remaining: $2.4M
- Investors: 19
- Date of first sale: 2020-09-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-376252
Issuer
- Name: Cedilla Therapeutics, Inc.
- CIK: 0001824618
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 245 FIRST STREET, CAMBRIDGE, MA, 02142
- Phone: 617- 281-5658
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Chris Bowden | Director | Brisbane, C3 |
| Alexandra Glucksmann | Director | Medford, MA |
| Alexandra Glucksmann | Executive Officer | Medford, MA |
| Eli Casdin | Director | New York, NY |
| Jake Simson | Director | San Mateo, CA |
| ABBIE CELNIKER | Director | Mt. Arlington, NJ |
| Neil Exter | Director | Boston, MA |
| Dominik Naczynski | Director | Cambridge, MA |
| Rosana Kapeller | Director | Cambridge, MA |
Other filings by this issuer (2)
More